Síndrome metabólico, resistencia a la insulina y disfunción cognitiva

Referencias bibliográficas: 

1. World Health Organization. Global report on diabetes. 2016.

2. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global,cregional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Dec;386 (10010):2287–323.

3. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996 Nov; 39 (11):1392–7.

4. Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation. 2005; 112(20).

5. Anderson PJ, Critchley JAJH, Chan JCN, Cockram CS, Lee ZSK, Thomas GN, et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes. 2001 Dec; 25(12):1782–8.

6. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain.2005;128(5).

7. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992 Jul; 15 (7):815–9.

8. De Felice FG, Lourenco M V., Ferreira ST. How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s Dement. 2014; 10 (1):S26–32.

9. Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: its

pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Front Endocrinol (Lausanne). 2014; 5:161.

10. Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015; 47:e149.

11. Stanley M, Macauley SL, Holtzman DM. Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? J Exp Med. 2016 Jul 25;213 (8):1375–85.

12. Neergaard JS, Dragsbak K, Kehlet SN, Hansen HB, Hansen G, Byrjalsen I, et al. Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study. Int J Epidemiol. 2016 Oct 27; dyw251.

13. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation- Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983 Jun;140(6): 734–9.

14. Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in old people. Br J Psychiatry.1973 Oct;123(575):467–70.

15. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006 May; 23(5):469–80.

16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 1 Jul; 28(7):412–9.

17. Pase MP, Beiser A, Enserro D, Xanthakis V, Aparicio H, Satizabal CL, et al. Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia. Stroke. 2016 May;47(5):1201–6.

18. Kern W, Benedict C, Schultes B, Plohr F, Moser A, Born J, et al. Low cerebrospinal fluid insulin levels in obese humans. Diabetologia. 2006 Oct 4; 49(11):2790–2.

7 19. Baura GD, Foster DM, Kaiyala K, Porte D, Kahn SE, Schwartz MW. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes. 1996 Jan; 45(1):86–90.

20. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004 Mar; 3(3):169–78.

21. Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, et al. Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle–Aged Adults at Risk for Alzheimer Disease. JAMA Neurol. 2015 Sep 1;72(9):1013.

22. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014 Jul; 63(7):2253–61.

23. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004 Feb; 53(2):474–81.

24. Fawver JN, Ghiwot Y, Koola C, Carrera W, Rodriguez-Rivera J, Hernandez C, et al. Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer’s disease. Curr Alzheimer Res. 2014;11 (10):928–40.